Angela J. Waanders, MD, MPH

Angela J. Waanders, MD, MPH, is an attending physician in the Neuro-Oncology Program at The Children's Hospital of Philadelphia. 

Areas of Expertise: Neuro-Oncology
Locations: Main Campus
Appointments and Referrals: 1-800-TRY-CHOP (1-800-879-2467)

  • Background

    My research focus is to develop novel therapeutic strategies and to improve the clinical outcomes for children with incurable brain tumors. As a pediatric hematology/oncology fellow, my work directly led to the discovery of an activated novel KIAA1549-BRAF fusion oncogene in the majority of pediatric low-grade gliomas (PLGGs). This genomic abnormality has since been found to be a hallmark of PLGGs. After fellowship, I continued my research in the laboratory of Dr. Adam Resnick. Our initial findings in PNAS in March 2013 and laid the foundation for understanding BRAF fusion signaling and has opened the door to several multi-institutional collaborations.

  • Education and Training

    Medical School

    MD - Tulane University School of Medicine, New Orleans, LA


    Pediatrics - The Children's Hospital of Philadelphia, Philadelphia, PA 


    Pediatric Hematology-Oncology - The Children's Hospital of Philadelphia, Philadelphia, PA

    Board Certification


    Graduate Degree

    MPH - Tulane University School of Public Health & Tropical Medicine, New Orleans, LA

  • Titles and Academic Titles

    Attending Physician

    Assistant Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania

  • Conditions Treated
  • Departments and Services
  • Research Interests

    Pediatric low grade gliomas
    Opsoclonus myoclonus ataxia syndrome

  • Publications



    Minturn JE, Sievert AJ. Pediatric brain tumors. In: Florin T, Ludwig S. Netter's pediatrics. Philadelphia: Saunders; 2011.



    Mueller S, Dik R, Yang X, Olow A, Gustafson C, DuBois S, Weiss W, Waanders AJ, Resnick, AC, and Haas-Kogan D. Effects of TORC1/2 inhibitor MLN0128 alone and in combination with MEK inhibition in BRAF mutated glioma cells. Neuro-Oncology. 17:iii1-iii40, 2015. Doi:10.1093/neuonc/nov061.75.

    Waanders AJ, Silva A, Chen SS, Han H, Zhu Y, Boucher K, Jain P, Fierst T, Choudhari N, Mueller S, Haas-Kogan D, Storm PB, Resnick AC. Combinatorial pathway targeting approaches for BRAF-fusions associated with pediatric low-grade gliomas. Neuro-Oncology. 17:iii1-iii40, 2015. Doi:10.1093/neuonc/nov061.151.

    Olow AK, Mueller S, Yang X, Hashizume R, Meyerowitz J, Weiss W, Resnick AC, Waanders AJ, Berger MS, Gupta N, James CD, Haas-Kogan DA. Targeted combinatorial approach for treatment of pediatric low-grade gliomas in the context of BRAF V600E and KIAA1549:BRAF mutations. Neuro-Oncology. 17:iii1-iii40, 2015. Doi:10.1093/neuonc/nov061.153.


    Sievert AJ, Lang SS, Silva A, Brewington D, Mueller S, Haas-Kogan DA, Storm PB, Resnick AC. Rationale for combinatorial therapeutics to inhibit BRAF fusion activation. Mol Cancer Ther. Nov 2013. 12:B272, doi:10.1158/1535-7163.



    Karajannis MA, Legault G, Fisher MJ, Milla SS, Cohen KJ, Wisoff JH, Harter DH, Goldbery JD, Hochman T, Merkelson A, Bloom MC, Sievert AJ, Resnick AC, Dhall G, Jones DTW, Korshunov A, Pfister SM, Eberhart CG, Zagzag D, and Allen JC. Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. Neuro Oncol. 2014 May 6. [Epub ahead of print]. PMID: 24803676

    Goldberg EM, Titulaer M, de Blank PM, Sievert A, Ryan N. Anti-N-methyl-D aspartate receptor-mediated encephalitis in infants and toddlers: case report and review of literature. Pediatr Neurol 2014 Feb; 50(2): 181-4. Doi: 10.1016/j.pediatrneurol.2013.10.002. Epub 2013 Oct 14. 


    Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, Kellet M, Storm PB, and Resnick AC. Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas. PNAS 2013 April; 110 (15): 5957-5962. Epub 2013 Mar 26. PMID: 23533272

    Posters and Presentations

    Lectures by Invitation


    Waanders, AJ. “Opsoclonus Myoclonus Ataxia Syndrome,” Chair Clinical Conference, The Children’s Hospital of Philadelphia, Philadelphia, PA, May 2014.

    “Targeting activating BRAF mutations in pediatric gliomas,” Neurosurgery Grand Rounds, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, August 2014.


    Waanders, AJ. “Congenital brain tumors,” Abington Memorial Hospital Neonatology Grand Rounds, Abington Township, PA, November 2013.

    Waanders, AJ. “Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas,” 2013 Pediatric Neuro-Oncology Basic and Translational Research Conference, Fort Lauderdale, FL, May 2013.

  • Awards and Honors

    2014- present, Sanford Endowed Chair for Pediatric Oncology Research
    2009,  Prize- CHOP Research Poster Day 
    1999-2003, Adopt-A-Student Scholarship, Tulane University SOM
    1996,  Philosophy Department Senior Student Award
    1992-1996, Alpha Lambda Delta Honorary Society
    1992-1996, Medallion and HEIS Scholarships for Academic Excellence

  • Editorial and Academic Positions

    Editorial Positions

    2013-present, Molecular Cancer Therapeutics, reviewer
    2012-present, Journal of Neuro-Oncology, reviewer
    2011-present, Pediatric Blood and Cancer, reviewer

    Academic and Institutional Committees

    2014-present,  St. Baldrick’s Foundation, Grant Review Committee
    2011-present, Pediatric Protocol Review Committee, Division of Oncology, Children’s Hospital of Philadelphia

  • Leaderships
    Memberships in Professional Organizations

    2013- present, Co-Investigator, Pacific Pediatric Neuro-Oncology Consortium
    2009- 2012, Pediatric Brain Tumor Consortium
    2008- present, American Association for Cancer Research
    2007- present, Society of Neuro-Oncology
    2007- present, Children’s Oncology Group
    2006- present,  American Society of Pediatric Hematology/Oncology
    2006-present, American Society of Clinical Oncology